Edgewise Therapeutics (EWTX) Set to Announce Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.5218) per share and revenue of $119.23 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.06). On average, analysts expect Edgewise Therapeutics to post ($2.09) EPS for the current fiscal year and ($1.78) EPS for the next fiscal year.

Edgewise Therapeutics Price Performance

NASDAQ:EWTX opened at $38.11 on Tuesday. Edgewise Therapeutics has a 12-month low of $16.70 and a 12-month high of $48.51. The firm has a market capitalization of $4.14 billion, a P/E ratio of -20.60 and a beta of 0.35. The business has a 50 day simple moving average of $41.22 and a 200 day simple moving average of $36.30.

Insider Activity at Edgewise Therapeutics

In related news, CMO Joanne Donovan sold 2,919 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $43.41, for a total value of $126,713.79. Following the completion of the transaction, the chief marketing officer owned 8,625 shares in the company, valued at $374,411.25. This represents a 25.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel John R. Moore sold 5,016 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $43.82, for a total transaction of $219,801.12. Following the completion of the transaction, the general counsel owned 17,697 shares of the company’s stock, valued at $775,482.54. This represents a 22.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,329 shares of company stock valued at $1,675,529 in the last ninety days. Company insiders own 21.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Evercore reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Edgewise Therapeutics in a research report on Monday, July 20th. HC Wainwright reissued a “buy” rating on shares of Edgewise Therapeutics in a report on Wednesday, October 14th. Guggenheim upped their price target on shares of Edgewise Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. William Blair began coverage on shares of Edgewise Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Oppenheimer started coverage on shares of Edgewise Therapeutics in a research report on Thursday, July 9th. They issued an “outperform” rating and a $51.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.33.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.